Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, 3000
- UZ Leuven
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- histologically proven endometriosis with complete treatment of all endometriosis lesions during laparoscopy
- only first three ART cycles
- normal uterine cavity
- Eligible for ovarian stimulation with long agonist protocol
Exclusion Criteria:
- FSH>20 IU/L
- presence of large intramural fibroids (> 3 cm)
- <4 oocytes obtained in any previous fresh ART cycle
- ART with sperm derived from testicular biopsy
- ART with Preimplantation Genetic Diagnosis/Screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: oral oestroprogestogen pre-treatment
preparation with oral oestroprogestogens prior to downregulation in an assisted reproductive technology treatment (ART) cycle
|
oral oestroprogestogen
Other Names:
|
|
Experimental: gonadotropin-releasing hormone (GnRH) pre-treatment
preparation with gonadotropin-releasing hormone (GnRH) analogues prior to downregulation in an assisted reproductive technology treatment (ART) cycle
|
gonadotropin-releasing hormone (GnRH) agonist
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
clinical pregnancy rate per initiated ART cycle
Time Frame: participants will be followed for the duration of the ART cycle including the pregnancy test, an expected average of 10 weeks in the active comparator group and an expected average of 18 weeks in the experimental group
|
participants will be followed for the duration of the ART cycle including the pregnancy test, an expected average of 10 weeks in the active comparator group and an expected average of 18 weeks in the experimental group
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Thomas M D'Hooghe, MD, PhD, UZ Leuven
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Infertility
- Endometriosis
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Estrogens
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Hormonal
- Luteolytic Agents
- Contraceptive Agents, Male
- Ethinyl Estradiol
- Triptorelin Pamoate
- Dienogest
Other Study ID Numbers
Other Study ID Numbers
- S55300
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
NCT01936077CompletedInfertility, Female Infertility, Male Infertility
-
NCT00315029CompletedPregnancy | Male Infertility | Female Infertility
-
NCT02107521TerminatedMale Infertility | Female Infertility
-
NCT03670758UnknownUnexplained Female Infertility
-
NCT01859520CompletedMale Infertility | Unexplained Infertility
-
NCT04945265Not yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
NCT04184323WithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, Nonimplantation
-
NCT03323801CompletedMale Infertility, Azoospermia
-
NCT01331395TerminatedPrimary Female Infertility | Secondary Female Infertility
-
NCT07398924CompletedUnexplained Infertility | Female Infertility | Anovulatory Infertility
Clinical Trials on ethinylestradiol + dienogest
-
NCT07204093Active, not recruiting
-
NCT07164183Recruiting
-
NCT03945513Completed
-
NCT06316206CompletedEndometrial Polyp | Endometrial Diseases
-
NCT06324851CompletedEndometrial Polyp | Endometrial Diseases
-
NCT00563771Completed
-
NCT00631579CompletedLymphoma | Leukemia | Hyperuricemia
-
NCT06396208CompletedUltrasound Finding: Ovulation Inhibition, Ovarian Activities | Cervical Mucus | Serum Hormonal Profile